A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition: HER2-Positive Early Breast Cancer Interventions: Drug: Pertuzumab and Trastuzumab FDC SC; Drug: Pertuzumab IV; Drug: Trastuzumab IV Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials